Medscape InDiscussion: Schizophrenia - podcast cover

Medscape InDiscussion: Schizophrenia

Medscapewww.medscape.com
Listen to Medscape InDiscussion: Schizophrenia, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984480). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Last refreshed:
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Download Metacast podcast app
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episodes

S2 Episode 6: Is MDMA a Potential Treatment for Negative Symptoms of Schizophrenia? Exploring Stigma and Strategies to Alleviate Symptoms

Drs John M. Kane and Mitchell Arnovitz discuss assessment of patients for negative symptoms of schizophrenia and the potential of MDMA in alleviating these symptoms in supervised treatment settings. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984490). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Schizophrenia ...

Jul 20, 202322 minSeason 2Ep. 6

S2 Episode 5: First-Episode Schizophrenia: The Importance of Engaging and Educating Patients and Their Families in Treatment

Drs John M. Kane and Delbert G. Robinson discuss psychoeducation, treatment options, and possible side effects of medication for patients experiencing their first episode of schizophrenia. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984489). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Schizophrenia https://em...

Jun 21, 202322 minSeason 2Ep. 5

S2 Episode 4: Common and Commonly Unrecognized: Clinical High-risk Syndrome, Psychosis, and Schizophrenia

Drs John M. Kane and Scott W. Woods discuss clinical high-risk syndrome and schizophrenia, including assessment methods, interventions, and risk indicators for future psychosis. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984484). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Schizophrenia https://emedicine.med...

May 23, 202319 minSeason 2Ep. 4

S2 Episode 3: Psychiatric Comorbidity in Schizophrenia: Assessing Patients and the Impact on Treatment Decisions and Outcomes

Drs John M. Kane and Christoph U. Correll discuss the importance of ongoing assessment of psychiatric comorbidities in patients with schizophrenia and its impact on outcomes and treatment decisions. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984483). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Schizophrenia ...

Apr 19, 202325 minSeason 2Ep. 3

S2 Episode 2: Long-Acting Injectables and Schizophrenia: Mitigating the Risk for Relapse and Rehospitalization

Drs John M. Kane and Jose Rubio-Lorente discuss the value of long-acting injectable formulations in reducing the risk for relapse and rehospitalization for patients diagnosed with schizophrenia. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984482). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Schizophrenia http...

Mar 22, 202324 minSeason 2Ep. 2

S2 Episode 1: Treatment-Resistant Schizophrenia: Detection, Management, and the Importance of Early Initiation of Treatment

Drs John M. Kane and Jonathan Meyer discuss treatment-resistant schizophrenia, how common it is, how to detect and manage it, and how delays in the initiation of treatment negatively affect patients. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984480). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources The Clozapine...

Mar 22, 202326 minSeason 2Ep. 1

S1 Episode 6: Relapse in Schizophrenia: Why It Occurs, How Often It Occurs, and What We Can Do About It

Drs John Kane and Jose Rubio-Lorente discuss relapse in schizophrenia — why it occurs, how often it occurs, and what we can do about it. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969531). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Schizophrenia https://www.medscape.com/resource/schizophrenia Schizophrenia C...

Dec 07, 202224 minSeason 1Ep. 6

S1 Episode 5: Neuroimaging in Schizophrenia: What Have We Learned?

Drs John Kane and Anil Malhotra discuss neuroimaging and connectivity between various regions of the brain in patients with schizophrenia and how it impacts the pathophysiology and treatment response. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969530). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Schizophrenia...

Nov 09, 202222 minSeason 1Ep. 5

S1 Episode 4: How Can We Assess Cognitive Functioning in Patients With Schizophrenia? And What Can We Do About It?

Drs John Kane and Philip D. Harvey discuss how physicians can assess cognitive functioning in patients with schizophrenia and how to utilize rehabilitation and technology to address it. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969529). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Schizophrenia https://www.me...

Oct 05, 202225 minSeason 1Ep. 4

S1 Episode 3: What New Antipsychotic Drugs Are Available for Schizophrenia? What Drugs Are Under Development? And What Do They Potentially Offer?

Drs John Kane and Jonathan M. Meyer discuss what new antipsychotic drugs are available for schizophrenia. What drugs are under development? And what do they potentially offer? Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969528). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources The Clozapine Handbook: Stahl's Handbo...

Sep 13, 202223 minSeason 1Ep. 3

S1 Episode 2: Antipsychotics in Schizophrenia: Effectiveness and Optimal Dosing

Drs John Kane and Stefan Leucht discuss the effectiveness and optimal dosing of antipsychotic medications in the treatment of schizophrenia. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969527). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Toward a Phenomenological Psychotherapy for Schizophrenia https://www.kar...

Aug 02, 202226 minSeason 1Ep. 2

S1 Episode 1: What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications?

Drs John Kane and Christoph U. Correll discuss the major metabolic and neurologic risks associated with antipsychotic medications for patients diagnosed with schizophrenia. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969525). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Schizophrenia https://www.medscape.com/re...

Aug 02, 202225 minSeason 1Ep. 1
Hosted on Libsyn
For the best experience, listen in Metacast app for iOS or Android